Abstract

Background: Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous drug reaction presenting with rapid-onset sterile pustules on edematous erythema.

Case: A 12-year-old female patient with acute gastroenteritis was consulted with complaints of pruritic erythema and high fever developing with small pustules on the 2nd day of ceftriaxone treatment. Lab tests showed an elevated absolute neutrophil count and lymphopenia. Ceftriaxone was discontinued immediately. The fever went away within 24 hours. According to EuroSCAR, the diagnosis of AGEP was confirmed. The skin biopsy was compatible with AGEP. After 6 weeks, a patch test with ceftriaxone was performed. A strong positive reaction to ceftriaxone was detected. Three months later, amoxicillin, amoxicillin-clavulanate, clarithromycin, and trimethoprim/sulfamethoxazole patch tests were performed, all were negative, and provocation tests were also planned.

Conclusion: AGEP is a severe cutaneous drug reaction. We wanted to emphasize that patch tests help identify the responsible drug and find a safe alternative.

Keywords: Acute generalized exanthematous pustulosis, drug eruption, patch test, severe drug hypersensitivity reactions

Copyright and license

Copyright © 2023 The author(s). This is an open-access article published by Aydın Pediatric Society under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Türkyılmaz Uçar Ö, Gökmirza Özdemir P, Kaplan Sarıkavak S, Can N, Yazıcıoğlu M. Ceftriaxone induced acute generalized exanthematous pustulosis confirmed with patch test. Trends in Pediatrics. 2023;4(3):217-221. https://doi.org/10.59213/TP.2023.27247

References

  1. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157:989-96. https://doi.org/10.1111/j.1365-2133.2007.08156.x
  2. Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168:555-62. https://doi.org/10.1111/bjd.12125
  3. Hammerbeck AA, Daniels NH, Callen JP. Ioversol-induced acute generalized exanthematous pustulosis: a case report. Arch Dermatol. 2009;145:683-7. https://doi.org/10.1001/archdermatol.2009.100
  4. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)-a clinical reaction pattern. J Cutan Pathol. 2001;28:113-9. https://doi.org/10.1034/j.1600-0560.2001.028003113.x
  5. Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991;127:1333-8.
  6. Beylot C, Doutre MS, Beylot-Barry M. Acute generalized exanthematous pustulosis. Semin Cutan Med Surg. 1996;15:244-9. https://doi.org/10.1016/s1085-5629(96)80037-x
  7. Navarini AA, Simpson MA, Borradori L, Yawalkar N, Schlapbach C. Homozygous missense mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis. JAMA Dermatol. 2015;151:452-3. https://doi.org/10.1001/jamadermatol.2014.3848
  8. Kakeda M, Schlapbach C, Danelon G, et al. Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. Arch Dermatol Res. 2014;306:933-8. https://doi.org/10.1007/s00403-014-1488-0
  9. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129:79-88. https://doi.org/10.1038/jid.2008.194
  10. Fernando SL. Acute generalised exanthematous pustulosis. Australas J Dermatol. 2012;53:87-92. https://doi.org/10.1111/j.1440-0960.2011.00845.x
  11. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013;68:693.e1-14; quiz 706-8. https://doi.org/10.1016/j.jaad.2013.01.033
  12. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.e1-13; quiz 185-6. https://doi.org/10.1016/j.jaad.2013.05.003
  13. Das S, Biswas P, Pal D, De A. Stamping a case of cutaneous adverse drug reaction: proving beyond causality assessment. Indian J Dermatol. 2018;63:99-106. https://doi.org/10.4103/ijd.ijd_580_17
  14. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005;209:209-16. https://doi.org/10.1016/j.tox.2004.12.024
  15. Barbaud A. Drug skin tests and systemic cutaneous adverse drug reactions: an update. Expert Review of Dermatology. 2007;2:481-95. https://doi.org/10.1586/17469872.2.4.481
  16. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003;58:854-63. https://doi.org/10.1034/j.1398-9995.2003.00279.x
  17. Gréco M, Plantin P. Acute generalized exanthematous pustulosis (AGEP) induced by terbinafine with involuntary positive reintroduction. Eur J Dermatol. 2005;15:116.
  18. Barbaud A, Gonçalo M, Bruynzeel D, Bircher A; European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001;45:321-8. https://doi.org/10.1034/j.1600-0536.2001.450601.x
  19. Buonomo A, Nucera E, Pecora V, et al. Cross-reactivity and tolerability of cephalosporins in patients with cell-mediated allergy to penicillins. J Investig Allergol Clin Immunol. 2014;24:331-7.